An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

NCT05492877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Mitiperstat (AZD4831)
OTHER: Placebo

Sponsor

AstraZeneca